News
7h
Investor's Business Daily on MSNThe Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.'Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety ...
Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...
Teijin Automotive Technologies has announced its name: CSP. This rebranding, effective July 1, 2025, marks the company’s ...
This week on "The Readout LOUD" podcast, a mother whose son has Duchenne muscular dystrophy shares her perspective on Sarepta ...
The top financial leader at Thermo Fisher Scientific Inc. plans to retire from the company in 2026 after more than a decade ...
Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...
Professional investors don't guess which stocks will explode - they use proven systems to identify them early. See Tim Melvin ...
To suggest Sarepta Therapeutics may not survive its gene therapy crisis is a sobering claim to make, STAT's Adam Feuerstein ...
This Massachusetts-based biopharmaceutical company announced hundreds of layoffs last week. Here's what the CEO said about it ...
For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...
Roche has halted some international shipments of the gene therapy Elevidys, used to treat Duchenne muscular dystrophy, Bloomberg reported July 22. The decision comes in the wake of a similar move by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results